Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

Years ago, Robyn Munsch would wander hungrily around the grocery store and leave with calorie-dense foods like a frozen pizza ...

GLP-1 medicines can be helpful tools for the treatment of obesity and for other important health goals, but they’re not for ...

While some Americans might feel doubtful about prescriptions, others are doing all they can to acquire GLP-1 drugs. Carly ...

Fridays weight loss is a telehealth provider that offers access to popular GLP-1 medications, including compounded versions ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

The rising use of GLP-1 agonists to help manage the obesity epidemic is not only reshaping how consumers taking the ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Many people experience a serious return of appetite, cravings and weight after coming off Ozempic, and having read far too ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m.